Vast Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Vast Therapeutics's estimated annual revenue is currently $2.4M per year.
- Vast Therapeutics's estimated revenue per employee is $201,000
Employee Data
- Vast Therapeutics has 12 Employees.
- Vast Therapeutics grew their employee count by 0% last year.
Vast Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | VP Translational Science | Reveal Email/Phone |
4 | VP Product Development | Reveal Email/Phone |
5 | Medical Director | Reveal Email/Phone |
6 | Director Administration | Reveal Email/Phone |
7 | Chief Scientific Officer | Reveal Email/Phone |
8 | Principal Scientist Inhalation | Reveal Email/Phone |
9 | Executive Chairman | Reveal Email/Phone |
10 | Principal R&D Scientist | Reveal Email/Phone |
Vast Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.8M | 29 | 4% | N/A | N/A |
#2 | $3.2M | 16 | 0% | N/A | N/A |
#3 | $83.2M | 414 | 7% | N/A | N/A |
#4 | $31M | 154 | 56% | N/A | N/A |
#5 | $66.6M | 265 | 0% | $35M | N/A |
#6 | $10.9M | 54 | 6% | N/A | N/A |
#7 | $6.8M | 34 | -6% | N/A | N/A |
#8 | $165.7M | 216 | 14% | $250.7M | N/A |
#9 | $26.5M | 132 | -11% | $637.8K | N/A |
#10 | $49.4M | 246 | 6% | N/A | N/A |
What Is Vast Therapeutics?
This is the official page for Vast Therapeutics. Vast Therapeutics is an innovative, preclinical-stage pharmaceutical company focused on helping patients who suffer from severe respiratory diseases to breathe better and live life more fully. The company is being purpose-built using our proprietary nitric oxide platform technology. These preclinical assets were developed in collaboration with Dr. Mark Schoenfisch's lab at UNC Chapel Hill. Our technology gives us the unique ability to harness nitric oxide, a chemical compound that plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. By controlling its multiple mechanisms of action, we can create a platform to generate differentiated first-in-class biopolymer/macromolecules that are loaded with nitric oxide and suitable to be inhaled. Our ability to conveniently deploy nitric oxide on demand in an inhaled formulation will allow us to significantly improve patient outcomes in cystic fibrosis and other severe respiratory diseases. In vitro susceptibility testing against pathogens with our product have been completed and results indicate a broad spectrum of activity and high potency against serious bacterial pathogens. These include: Methicillin-resistant Staphylococcus aureus (MRSA) Methicillin-sensitive Staphylococcus aureus (MSSA) Pseudomonas aeruginosa Burkholderia cepacia Mycobacterium Avium-Intracellulare complex (MAC) Mycobacterium abscessus Achromobacter xylosoxidans Stenotrophomonas maltophilia Most of these pathogens present a significant threat to public health, according to the FDA. Notably, our product has shown efficacy against Mycobacterium abscessus, which is a growing pathogen among serious respiratory challenged patients.
keywords:N/AN/A
Total Funding
12
Number of Employees
$2.4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Vast Therapeutics News
... for Women's Health, Autism, Glaucoma, and Cancer Therapeutics ... M.D.: Nova's Psilocybin-based Therapeutics Showing Vast Promise for...
... Ms. Hamill has worked across a vast array of therapeutic areas, ... of Scilex Holding and Chair and CEO of Sorrento Therapeutics, Inc..
Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) CMO Marvin Hausman, M.D.: Nova's Psilocybin-based Therapeutics Showing Vast Potential...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1M | 12 | 0% | N/A |
#2 | $1M | 12 | 0% | N/A |
#3 | $1.6M | 12 | 0% | N/A |
#4 | $1M | 12 | N/A | N/A |
#5 | $0.9M | 12 | -20% | $7.1M |